1) La descarga del recurso depende de la página de origen
2) Para poder descargar el recurso, es necesario ser usuario registrado en Universia


Opción 1: Descargar recurso

Detalles del recurso

Descripción

Background: Tamoxifen, raloxifene, and exemestane have been demonstrated to reduce risk of breast cancer in high-risk women, bututilization is very low.Among the reasons cited are lack of awareness and reluctance of physicians to prescribe. Women with high-risk breast lesions are generally candidates for chemoprevention and can be evaluated and counseled in a high-risk breast clinic. Knowledge about drugs that can prevent breast cancer may increase uptake among high-risk women. Methods: In a single practice, women with a diagnosis of atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), or severe atypical ductal hyperplasia/borderline ductal carcinoma in situ are offered an extended visit with a nurse practitioner in the Breast and Ovarian Cancer Risk and Prevention Clinic. The visit includes data collection, patient interview about relevant history and personal preferences, risk assessment, including use of relevant models (via HughesRiskApps.com), and recommendations for surveillance and prevention. Emphasis is placed on understanding of individual risk as well as risks and benefits and appropriateness of chemoprevention and surveillance modalities. Based on personal and family history, women are advised if chemoprevention is appropriate to consider, their choice is made, and they are encouraged to have surveillance in the Breast Clinic. Results: Since January 2001, 487 women with a diagnosis of ADH, ALH or LCIS, or severe ADH have been evaluated and counseled in the Breast and Ovarian Cancer Risk and Prevention Clinic. 132/487 (27%) were advised against taking chemoprevention and 355/487 (73%) were appropriate for chemoprevention. Of those for whom chemoprevention was clinically appropriate, 188/355 (53%) took one of the medications, or participated in a chemoprevention trial. 53/188 (28%) did not complete therapy (discontinued at 2 weeks to 54 months) due to preference or side effects. 75 women have completed five years of therapy and 60 are currently on therapy. Conclusions: When provided with personalized information about breast cancer risk and the pros and cons of chemoprevention, many women will choose to take medication to reduce breast cancer risk.

Pertenece a

Digital Access to Scholarship at Harvard  

Autor(es)

Roche, Constance A. -  Hughes, Kevin S. - 

Id.: 71304142

Idioma: inglés (Estados Unidos)  - 

Versión: 1.0

Estado: Final

Tipo de recurso: Journal Article  - 

Tipo de Interactividad: Expositivo

Nivel de Interactividad: muy bajo

Audiencia: Estudiante  -  Profesor  -  Autor  - 

Estructura: Atomic

Coste: no

Copyright: sí

: open

Requerimientos técnicos:  Browser: Any - 

Relación: [References] doi:10.1200/jco.2012.30.27_suppl.46
[References] Journal of Clinical Oncology

Fecha de contribución: 13-may-2018

Contacto:

Localización:
* Roche, Constance A., and Kevin S. Hughes. 2012. “A Program to Increase Use of Chemoprevention for Women with High-Risk Breast Lesions.” Journal of Clinical Oncology 30 (27_suppl) (September 20): 46–46. doi:10.1200/jco.2012.30.27_suppl.46.
* 0732-183X

Otros recursos del mismo autor(es)

  1. Breast cancer risk assessment: How risk models can “overdiagnose” risk. Background: Overdiagnosis is commonly defined as a diagnosis of "disease" which will never cause sym...
  2. Reply to E. Ramos et al
  3. Long-term Risk of False-Positive Screening Results and Subsequent Biopsy as a Function of Mammography Use
  4. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of indications for resection In an investigation of the indications for hepatic resection in the treatment of colorectal carcinom...
  5. Prediction of primary breast cancer size and T-stage using micro-computed tomography in lumpectomy specimens Background: Histopathology is the only accepted method to measure and stage the breast tumor size. H...

Otros recursos de la mismacolección

  1. Functional Connectivity Is Associated With Altered Brain Chemistry in Women With Endometriosis-Associated Chronic Pelvic Pain
  2. Demonstration of vasoproliferative activity from mammalian retina Vasoproliferative activity has been demonstrated in extracts of retinas from human, bovine, and feli...
  3. Skeletal defects in VEGF120/120 mice reveal multiple roles for VEGF in skeletogenesis Angiogenesis is an essential component of skeletal development and VEGF signaling plays an important...
  4. Distribution of [1,2-3H]cholesterol in mouse brain after injection in the suckling period Glutaraldehyde-carbohydrazide polymer (GACH) was used to embed olfactory tracts, trapezoid body, and...
  5. A 44-year-old man with eye, kidney, and brain dysfunction Retinal vasculopathy with cerebral leukodystrophy (RVCL) is a rare, autosomal dominant condition cau...

Aviso de cookies: Usamos cookies propias y de terceros para mejorar nuestros servicios, para análisis estadístico y para mostrarle publicidad. Si continua navegando consideramos que acepta su uso en los términos establecidos en la Política de cookies.